Antihistamines effectively inhibit histamine-mediated symptoms, such as sneezing and nasal discharge, because they have the ability to block histamine (H 1 ) receptors (Tarnasky and Van Arsdel, 1990; Wang et al., 2001) . Loratadine is a widely prescribed, non-sedating antihistamine with selective peripheral histamine H 1 -receptor antagonist activity that is not associated with performance impairment and has an excellent safety record (Bradley and Nicholson, 1987; Ramaekers et al., 1992; Kay et al., 1997; Philpot, 2000; Prenner et al., 2000) . Loratadine is orally administered and is used to treat allergy symptoms, including sneezing, watery eyes, and runny nose. It is also used to treat skin hives and itching in people with chronic skin reactions. It has been widely used due to its effi cacy in the treatment of allergic symptoms and lack of signifi cant central and autonomic nervous side effects such as sedation and anticholinergic properties (Clissold et al., 1989) .
INTRODUCTION

Abstract
Loratadine undergoes extensive fi rst-pass metabolism in the liver (Hilbert et al., 1987) and CYP3A4 enzymes are responsible for the metabolism of loratadine (Yumibe et al., 1996) . Loratadine is also a substrate of P-gp (Wang et al., 2001) . Since P-gp is co-localized with CYP3A4 in the small intestine, P-gp and CYP3A4 may act synergistically in absorption and fi rst-pass metabolism of drugs, respectively (Pichard et al., 1990; Wacher et al.,1998; Ito et al., 1999) .
Curcumin is the major yellow pigment in turmeric, curry, and mustard and has been widely used in cosmetics and drugs (Govindarajan, 1980) . Studies on the chemopreventive effi cacy of curcumin have shown that it possesses both antiinitiating and antipromoting activities in several experimental systems (Huang et al., 1994; Deshpande et al., 1998) . There are also reports that curcumin inhibits carcinogenesis in various tissues, including skin (Huang et al., 1997) , colorectal (Rao et al., 1995) , oral (Tanaka et al., 1994) , forestomach (Singh et al., 1998) and mammary (Singletary et al., 1998) cancers. In
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Biomol Ther 19(3), 364-370 (2011) www.biomolther.org www.biomolther.org vitro and animal studies have suggested that curcumin may have antitumor (Aggarwal and Shishodia, 2006; Choi et al., 2006) , antioxidant, antiarthritic, anti-amyloid, anti-ischemic (Shukla et al., 2008) and anti-infl ammatory properties (Srivastava et al., 1995) . Appiah-Opong et al. (2008) reported that curcumin inhibits human CYP3A4, 2C9 and 2D6, while Thapliyal and Maru, (2001) found that curcumin inhibits human CYP1A1, 1A2 and 2B1. Thus, the inhibitory effects of curcumin against human CYP enzymes remain somewhat controversial. Curcumin is an inhibitor of P-gp in the KB/MDR cell line (Efferth et al., 2002) , but the inhibitory effect of curcumin against P-gp is ambiguous elsewhere. Therefore, we re-evaluated the inhibition of CYP enzyme activity and P-gp activity by curcumin using CYP inhibition assays and rhodamine-123 retention assays in P-gp-overexpressing MCF-7/ADR cells.
Loratadine and curcumin interact with CYP enzymes and P-gp, and the tremendous increase in the use of health supplements may result in curcumin being taken concomitantly with loratadine to treat dermatological or allergic diseases as a combination therapy. It is important to assess the potential pharmacokinetic interactions after the concurrent use of loratadine and curcumin or curcumin-containing dietary supplements in order to assure the effectiveness and safety of drug therapy. However, the possible effects of curcumin on the bioavailability and pharmacokinetics of loratadine have not been reported. Since loratadine and curcumin share the same CY-P3A4-directed metabolic pathways, metabolism of loratadine may be competitively inhibited by curcumin. The aim of the current study was therefore to investigate the possible effects of curcumin on the pharmacokinetics of loratadine after oral and intravenous administration in rats. 
MATERIALS AND METHODS
Chemicals and apparatus
Animal experiments
Male Sprague-Dawley rats, 7-8 weeks old (270-300 g), were purchased from Dae Han Laboratory Animal Research Co. (Choongbuk, Republic of Korea) and were given free access to commercial rat chow diet (No. 322-7-1, Superfeed Co., Gangwon, Republic of Korea) and tap water ad libitum. The animals were housed (four or fi ve per cage) in laminar fl ow cages maintained at 22 ± 2 o C and 50-60% relative humidity under a 12:12 h light-dark cycle. The experiments began after acclimation to these conditions for at least one week. The experiments were carried out in accordance with the "Guiding Principles in the Use of Animals in Toxicology" adopted by the Society of Toxicology (USA) in July 1989 and revised in March 1999. The Animal Care Committee of Chosun University (Gwangju, Republic of Korea) approved the design and the conduct of this study.
The rats were fasted for at least 24 h prior to beginning the experiments and had free access to tap water. Each animal was lightly anaesthetized with ether, and the femoral artery and vein were cannulated using polyethylene tubing (SP45, I.D. 0.58 mm, O.D. 0.96 mm; Natsume Seisakusho Co. LTD., Tokyo, Japan) for blood sampling and intravenous administration.
Oral and intravenous administration of loratadine
The rats were divided into seven groups (n=6, each): the oral group (4.0 mg · kg −1 of loratadine dissolved in water, homogenized at 36 o C for 30 min) without (control) or with 0.5 mg · kg −1 , 2.0 mg · kg −1 or 8.0 mg · kg −1 of oral curcumin; the intravenous group (1.0 mg · kg −1 of loratadine, dissolved in 0.9% NaCl solution, homogenized at 36 o C for 30 min) without (control) or with 2.0 mg · kg −1 or 8.0 mg · kg −1 of oral curcumin. Oral loratadine was administered intragastrically using a feeding tube, and curcumin was intragastrically administered 30 min before administration of loratadine. Loratadine for intravenous administration was injected through the femoral vein within 0.5 min.
Blood samples (0.35 ml) were collected into heparinized tubes via the femoral artery at 0 (as a control), 0.017 (at the end of infusion), 0.1, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h after intravenous infusion, and 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 h after oral administration. Blood samples were immediately centrifuged for 3 min at 13,000 rpm and 0.2-ml aliquots of plasma were stored in a −40 o C freezer until HPLC analysis of loratadine. Approximately 0.9 ml of whole blood collected from untreated rats was infused via the femoral artery at 0.5, 2, 4 and 8 h to replace the blood lost due to blood sampling.
HPLC assay
The plasma concentrations of loratadine were determined by the HPLC assay modifi ed from the methods of Yin et al. (2003) and Amini and Ahmadiani (2004) . Briefl y, 50 μl of propranolol (0.21 μg · ml −1 , as the internal standard), 50 μl of 2 N sodium hydroxide solution and 1.1 ml of diethyl ether were added to 0.2 ml of the plasma samples. The mixture was then stirred for 3 min and centrifuged at 13,000 rpm for 10 min. 1.0 ml of the organic layer was transferred to a clean test tube and evaporated at 35 o C under a stream of nitrogen. The residue was dissolved in 150 μl of the mobile phase and centrifuged at 13,000 rpm for 5 min. A 70-μl aliquot of the supernatant was injected into the HPLC system. Fluorescence detection was performed at excitation and emission wavelengths of 290 and 460 nm. The stationary phase was a Kromasil KR 100-5C 8 column (150×4.60 mm, 5 μm, EKA chemicals, Sweden) and the mobile phase was methanol/acetonitrile/0.05 M KH 2 PO 4 (3:30:67, v/v/v, pH 2.0 adjusted with phosphoric acid). The retention times at a fl ow rate of 1.2 ml · min −1 was as follows: internal standard at 4.49 min and loratadine at 11.86 min. The calibration curves of loratadine were linear within the range of 10-500 ng · ml −1 . The coeffi cients of variation were less than 13.3% for loratadine.
CYP 3A4 inhibition assay
The assay of inhibition of human CYP3A4 enzyme activity was performed in a multiwell plate using a CYP inhibition assay kit (GENTEST, Woburn, MA) as described previously (Crespi et al., 1997) . Briefl y, human CYP enzyme was obtained from baculovirus-infected insect cells. CYP substrate (7-BFC for CYP3A4) was incubated with or without test compounds in buffer containing the enzyme/substrate with 1 pmol of P450 enzyme and a NADPH-generating system (1.3 mM NADP, 3.54 mM glucose 6-phosphate, 0.4 U/ml glucose 6-phosphate dehydrogenase and 3.3 mM MgCl 2 ) in potassium phosphate buffer (pH 7.4). Reactions were terminated by adding stop solution after 45-min incubation. Metabolite concentrations were measured by spectrofl uorometer (Molecular Device, Sunnyvale, CA) at an excitation wavelength of 409 nm and an emission wavelength of 530 nm. Positive control (1 μM ketoconazole for CYP3A4) was run on the same plate and produced 99% inhibition. All experiments were performed in duplicate, and the results are expressed as the percent of inhibition.
Rhodamine-123 retention assay
The procedures used for the Rho-123 retention assay were similar to a previously reported method (Han et al., 2008) . MCF-7/ADR cells were seeded in 24-well plates. At 80% confl uence, the cells were incubated in FBS-free DMEM for 18 h. The culture medium was then changed to Hanks' balanced salt solution and the cells were incubated at 37 o C for 30 min. After incubation of the cells with 20 μM rhodamine-123 in the presence of curcumin (0, 1, 3 and 10 μM) for 90 min, the medium was completely removed. The cells were then washed three times with ice-cold phosphate buffer (pH 7.0) and lysed in lysis buffer. The rhodamine-123 fl uorescence in the cell lysates was measured using excitation and emission wavelengths of 480 and 540 nm, respectively. Fluorescence values were normalized to the total protein content of each sample and presented as the ratio to control.
Pharmacokinetic analysis
The plasma concentration data were analyzed using a noncompartmental method on WinNonlin software version 4.1 (Pharsight Co., Mountain View, CA, USA). The elimination rate constant (K el ) was calculated by the log-linear regression of loratadine concentration data during the elimination phase, and the terminal half-life (t 1/2 ) was calculated by 0.693/K el . The peak concentration (C max ) and time to reach the peak concentration (T max ) of loratadine in the plasma were obtained by visual inspection of the data in the concentration-time curve. The area under the plasma concentration-time curve (AUC 0-t ) from time zero to the time of the last measured concentration (C last ) was calculated using the linear trapezoidal rule. The AUC zero to infi nity (AUC 0-∞ ) was obtained by adding AUC 0-t and the extrapolated area was determined by C last /K el . The total body clearance for the i. www.biomolther.org in Fig. 1 . The IC 50 of curcumin on CYP3A4 activity was 2.71 μM. Higher concentrations of curcumin inhibited CYP3A4 enzyme activity in a concentration-dependent manner.
Rhodamine-123 retention assay
As shown in Fig. 2 , accumulation of rhodamine-123, a P-gp substrate, was reduced in MCF-7/ADR cells overexpressing P-gp compared to that in MCF-7 cells lacking P-gp. The concurrent use of curcumin enhanced the cellular uptake of rhodamine 123 in a concentration dependent manner and showed statistically signifi cant (p<0.01) increase at the concentration range of 10 μM. This result suggests that curcumin signifi cantly inhibits P-gp activity.
Eff ects of curcumin on the plasma concentrations after oral administration
The plasma concentration-time profi les of loratadine in the relative bioavailability (R.B.) was calculated by (AUC with curcumin / AUC control )×100
Statistical analysis
All the means are presented with their standard deviation. The pharmacokinetic parameters were compared using oneway analysis of variance (ANOVA), followed by a posteriori testing with the Dunnett correction. A p-value <0.05 was considered statistically signifi cant.
RESULTS
Inhibition of CYP3A4
The inhibitory effect of curcumin on CYP3A4 activity is shown Table 1 . Mean (± S.D.) pharmacokinetic parameters of loratadine after its oral administration (4.0 mg · kg presence and absence of curcumin were characterized in rats and illustrated in Fig. 3 . The mean pharmacokinetic parameters of loratadine are summarized in Table 1 . As shown in Table 1 , the presence of curcumin (2.0 or 8.0 mg · kg −1 ) significantly altered the pharmacokinetic parameters of loratadine compared to those in the control group given loratadine alone. Curcumin signifi cantly (2.0 mg · kg −1 , p<0.05; 8.0 mg · kg −1 , p<0.01) increased the AUC 0-∞ of loratadine by 39.4-66.7%. The C max was signifi cantly (2.0 mg · kg −1 , p<0.05; 8.0 mg · kg −1 , p<0.01) increased by 34.2-61.5% in the presence of curcumin. The A.B. of loratadine was signifi cantly increased 40.0-66.1% (2.0 mg · kg −1 , p<0.05; 8.0 mg · kg −1 , p<0.01) compared to that in the oral control group. Consequently, the R.B. of loratadine was increased by 1.39-to 1.67-fold. However, there were no signifi cant changes in the T max and the t 1/2 of loratadine in the presence of curcumin.
Eff ects of curcumin on the plasma concentrations after i.v. administration
The pharmacokinetic profi les of loratadine were also evaluated after its intravenous administration (1.0 mg · kg −1 ) in the presence or absence of curcumin (2.0 or 8.0 mg · kg −1 ) and illustrated in Fig. 4 . As summarized in Table 2 , curcumin had no effect on the pharmacokinetic parameters of intravenous loratadine although it had a signifi cant effect on the bioavailability of loratadine given orally, suggesting that curcumin may be mainly due to increased intestinal absorption caused via P-gp and CYP3A4 inhibition rather than to reduced renal and hepatic elimination of loratadine.
DISCUSSION
With the great interest in herbal components as alternative medicines, much effort is currently being expended to identify natural compounds of plant origin that modulate P-gp and metabolic enzymes, however, there is far less information on the pharmacokinetic interactions between herbal components and medicines. More preclinical and clinical investigations on the herbal constituents-drug interaction should be performed to prevent potential adverse reactions or to utilize those interactions for a therapeutic benefi t. Therefore, the present study evaluated the effect of curcumin, a naturally occurring fl avonoid, on the pharmacokinetics of loratadine in rats to examine a potential drug interaction between curcumin and loratadine via the dual inhibition of CYP3A4 and P-gp.
Loratadine has low bioavailability because of poor solubility and fi rst-pass metabolism in the liver and epithelial cells of the small intestine. Yumibe et al. (1996) reported that loratadine is metabolized by CYP 3A4 in both liver and small intestine. Since loratadine is also a substrate for the effl ux pump, P-gp (Wang et al., 2001) , the oral bioavailability of loratadine might be affected by this transporter. P-gp co-localized with CYP3A4 may function synergistically in regulating the bioavailability of many orally administered compounds (Pichard et al., 1990; Wacher et al., 1998; Ito et al., 1999) . Based on their broad overlap in substrate specifi cities as well as their co-localization in the small intestine, which is the primary site of absorption for orally administered drugs, CYP3A4 and P-gp are recognized as a concerted barrier to drug absorption (Wolozin et al., 2000; Cummins et al., 2002) . CYPs contribute signifi cantly to fi rstpass metabolism and oral bioavailability of many drugs. The fi rst-pass metabolism of compounds in the intestine limits the absorption of toxic xenobiotics and may ameliorate side effects. Moreover, induction or inhibition of intestinal CYPs may be responsible for signifi cant drug-drug interactions when one agent decreases or increases the bioavailability and absorption rate constant of a concurrently administered drug (Kaminsky and Fasco, 1991) .
As shown in Figs. 1 and 2 , curcumin inhibited CYP3A4 and P-gp. In this study, the presence of curcumin increased the AUC and C max of oral loratadine. Since curcumin acts as an inhibitor of effl ux transporters, i.e., P-gp, located in intestinal cells, the presence of curcumin might decrease the effl ux of loratadine by this transporter in the intestine. The enhanced oral bioavailability of loratadine contributed to the competitive inhibition of loratadine metabolism by CYP 3A4 both in the liver and intestine. This result was consistent with previous studies showing that a single oral administration of cimeti- www.biomolther.org dine, clarithromycin and ketoconazole signifi cantly increased the AUC and C max of loratadine in rats through inhibition of CYP3A4 (Carr et al., 1998; Kosoglou et al., 2000) . These results are coincident with previous studies, in which CYP3A9 expressed in rat is corresponds to the ortholog of CYP3A4 in human (Kelly et al., 1999) . Therefore, rats are frequently used to evaluate the potential pharmacokinetic interactions mediated by CYP3A4, although there may be some difference in enzyme activity between rat and human (Cao et al., 2006) .
In contrast to the oral pharmacokinetics of loratadine, the intravenous pharmacokinetics of loratadine was not affected by the concurrent use of curcumin. The total body clearance (CL t ) of loratadine tended to be decreased and the AUC of loratadine was increased, although these values were not statistically different from those in the control. The t 1/2 of loratadine was also increased but this was not signifi cant. These results were consistent with the report by Li et al. (2008) in that roxithromycin did not signifi cantly increase the AUC of intravenous loratadine, a substrate for P-gp and CYP3A4 in rats. Accordingly, while there was no signifi cant change in the intravenous pharmacokinetics of loratadine, the enhanced oral bioavailability in the presence of curcumin may be mainly caused by increased intestinal absorption via P-gp inhibition by curcumin rather than by reduced renal elimination of loratadine.
In conclusions, curcumin signifi cantly enhanced the oral bioavailability of loratadine in rats. The enhanced bioavailability of loratadine may be caused by inhibition of the CYP3A4-mediated metabolism of loratadine in the small intestine or in the liver and by inhibition of the P-gp effl ux pump in the small intestine by curcumin. Therefore, concomitant use of curcumin or curcumin-containing dietary supplements with loratadine may require close monitoring for potential drug interactions.
